Intelligence · Clinical pipeline
Oncology · Phase II
Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.
Quick answer
Oncology Phase II programs: NovaPharmaNews indexes 2,637 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.
Top sponsors
- First People's Hospital 261 programs
- Chinese Academy of 198 programs
- George Institute for 118 programs
- United Therapeutics Europe 112 programs
- Telethon Foundation 91 programs
- Takeda 79 programs
- Regeneron UK 71 programs
- MSD Merck Sharp 63 programs
- Ningbo Cancer Hospital 62 programs
- Anaxis Pharma 57 programs
- AstraZeneca 52 programs
- HOFFMANN-LA ROCHE 50 programs
Pipeline programs
-
CEMIPLIMAB
Fondazione Telethon ETS
surgically resectable, high risk stage III/IV (M0) Cutaneaous Squamous Cell Carcinoma, Cutaneaous Squamous Cell Carcinoma
1 trial -
CEP-701
Teva Pharma GmbH
Prostate Cancer
1 trial -
CEP-701
Teva Pharma GmbH
Acute Myeloid Leukemia
1 trial -
CEP-701 60mg
Teva Pharma GmbH
Leukemia, Myeloid
1 trial -
CEP-9722
Teva Pharma GmbH
Solid Tumors
1 trial -
CETUXIMAB for ADCC, Colorectal Cancer
Fondazione Telethon ETS
ADCC, Colorectal Cancer
1 trial -
CF102
Can-Fite BioPharma
Hepatocellular Carcinoma
2 trials -
CG0070
CG Oncology
Bladder Cancer
1 trial -
CG0070
CG Oncology
Non Muscle Invasive Bladder Cancer
1 trial -
CGT4859
Cogent Biosciences
Intrahepatic Cholangiocarcinoma (Icc)
1 trial -
CGT9486
Cogent Biosciences
Gastrointestinal Stromal Tumors
1 trial -
CGVV858A12101
Novartis Pharmaceuticals
Advanced HR+/HER- breast cancer
1 trial -
CHALLENGE
Fondazione Telethon ETS
stage III PD-L1 positive Non-Small Cell Lung Cancer (NSCLC)
1 trial -
CHO-H01
Cho Pharma
Non-Hodgkin Lymphoma
1 trial -
CHOP+selinexor+5-Azacitidine
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Peripheral T Cell Lymphoma
1 trial -
CIALIS 5 mg film-coated tablets
The George Institute
sexual/ erectile function in women and men after treatment for rectal cancer
1 trial -
CIBI3009A101
Talion
Extensive-Stage Small Cell Lung Cancer
1 trial -
CIK
The First People's Hospital of Lianyungang
Lung Adenocarcinoma
1 trial -
CIRCULATE-SPAIN-01
The George Institute
Localised Colon Cancer (stage II-III)
1 trial -
CJDQ443A12101
Novartis Pharmaceuticals
Advance solid tumors harboring the KRAS G12C mutation
1 trial -
CJDQ443E12101
Novartis Pharmaceuticals
Adult patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors
1 trial -
CJSB462B12201
Novartis Pharmaceuticals
Metastatic castration resistant prostate cancer (mCRPC)
1 trial -
CJSB462C12201
Novartis Pharmaceuticals
Metastatic hormone-sensitive prostate cancer
1 trial -
CL1-65487-003
The George Institute
Acute Myeloid Leukemia (AML)
1 trial -
CL1-95012-001
The George Institute
Soild Tumors
1 trial -
CL1-95029-002
The George Institute
MSI-H/dMMR Gastric cancer, MSI-H/dMMR Gastroesophageal-junction Cancer
1 trial -
CL1-95035-001
The George Institute
MTAP-deleted advanced or metastatic solid tumors
1 trial -
CLARITY-PT01
AstraZeneca AB
Gastric Cancer, Gastroesophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer
1 trial -
CLEAN-DUCT
The George Institute
Extrahepatic cholangiocarcinoma (eCCA)
1 trial -
CLEE011Q12101
Novartis Pharmaceuticals
Relapsed or refractory neuroblastoma and other solid tumors (including medulloblastoma, high grade glioma, malignant rhabdoid tumors, and rhabdomyosarcoma)
1 trial -
CLEE011X2107
Novartis Pharmaceuticals
Advanced HR+ breast cancer
1 trial -
CLEE011X2X01B
Novartis Pharmaceuticals
Different types of advanced cancer
1 trial -
CLIN-01194-450
Ipsen
Pancreatic Ductal Adenocarcinoma, Melanoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Solid tumors
1 trial -
CLN-081
Cullinan Therapeutics
Non Small Cell Lung Cancer
1 trial -
CLN-081, CLN-081
Cullinan Therapeutics
Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
1 trial -
CLXH254C12201
Novartis Pharmaceuticals
Previously treated unresectable or metastatic BRAFV600 or NRAS mutant melanoma
1 trial -
CM-24 and Nivolumab - Dose Escalation
PURPLE BIOTECH LTD.
Solid Tumor
1 trial -
CMB305
Lxo Ireland Designated Activity Company
Sarcoma
2 trials -
CMBG453B12206B
Novartis Pharmaceuticals
intermediate, high or very high risk MDS in adult patients chronic Myelomonocytic Leukemia - 2 (CMML-2) Acute Myeloid Leukemia (AML) in adult patients unfit for chemotherapy
1 trial -
CML1624
Fondazione Telethon ETS
BCR-ABL1+ Chronic Myeloid Leukemia
1 trial -
CMP-001
Regeneron UK Limited
Squamous Cell Carcinoma of Head and Neck
1 trial -
CMP-001-009
Lacuna Pharma Pty Ltd
Advanced or Metastatic Cancer Merkel Cell Carcinoma (MCC) Cutaneous Squamous Cell Carcinoma (CSCC) Basal Cell Carcinoma (BCC) Triple Negative Breast Cancer (TNBC) Non-Small Cell Lung Cancer (NSCLC)
1 trial -
CMUH-HO-NPC001
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Locally Advanced Head and Neck Carcinoma
1 trial -
CNAO 44 2021C
Fondazione Telethon ETS
Unresectable or metastatic melanoma, Locally advanced or metastatic urothelial carcinoma, Locally advanced or metastatic non-small cell lung cancer (NSCLC), Untreated recurrent/metastatic head & neck sqamous cell carcinoma (HNSCC)
1 trial -
CNCT19
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Large B-cell Lymphoma
1 trial -
CO40115
Hoffmann-La Roche
Metastatic breast cancer, including triple negative breast cancer (TNBC), hormone receptor positive breast cancer (HR+ BC), and HER2 positive and HER2 low breast cancer (HER2+/HER2-low BC)
1 trial -
CO40778
Hoffmann-La Roche
Pediatric Solid tumors and primary central nervous system (CNS) tumors
1 trial -
CO41942
Hoffmann-La Roche
Follicular Lymphoma (FL)
1 trial
Frequently asked questions
How many oncology Phase II programs exist?
2,637 programs match both the therapeutic area and stage filters in our published index.